#United States #San Mateo #Talphera #Nafamostat #NEPHRO

Talphera's Third Quarter 2026 Financial Results and Business Update

Talphera, Inc., a specialty pharmaceutical company, has made significant strides in the third quarter of 2026. As it continues to develop nafamostat as a regional anticoagulant for continuous renal replacement therapy (CRRT), the company has released its financial overview and updated information regarding its ongoing clinical studies.

The NEPHRO CRRT study aims to evaluate the efficacy of nafamostat in critically ill patients who cannot tolerate heparin. Despite the challenges faced in patient enrollment, which has slowed due to a decrease in eligible patients at clinical sites, Talphera remains optimistic about the study's outcomes. CEO Vince Angotti noted that enrollment has reached more than 75% of the initial target of 70 patients. However, to address the current challenges, the company has submitted a briefing document to the FDA, requesting feedback on potentially closing the study enrollment by December 31, 2026, even if fewer patients are enrolled.

In addition, Angotti expressed confidence in the updated market potential for nafamostat, citing new qualitative and quantitative research that estimates peak sales for the compound could exceed $200 million. This increased projection is supported by positive feedback from medical professionals regarding nafamostat's advantages over existing anticoagulants.

Financial Highlights

Talphera reported a total balance of cash and investments amounting to $14.2 million as of September 30, 2026. Research and development (R&D) activities and selling, general, and administrative expenses (SGA) were reported to be $4.1 million for the quarter, an increase from the previous year's $3.4 million.

The company posted a net loss attributable to common shareholders of $4.0 million, translating to a loss of $0.05 per basic and diluted share. This marks a slight improvement from the prior year, where the net loss was $4.4 million, or $0.11 per share.

Approximately $292,000 of the expenses in this quarter were due to non-cash stock-based compensation, indicating ongoing investments in the workforce. Talphera also plans to file a new Form S-3 Shelf Registration Statement as its existing one approaches expiration.

The NEPHRO CRRT Study

The NEPHRO study is significant as it targets a challenging patient demographic—those critically ill and at risk of bleeding, thereby unable to use traditional coagulation treatments. This blinded, prospective trial, conducted across 14 intensive care units in the U.S., aims to assess the efficacy and safety of nafamostat.

The primary endpoint of the trial focuses on measuring the mean post-filter activated clotting time when using nafamostat as opposed to a placebo, over the initial 24 hours following treatment. Furthermore, secondary endpoints will include several metrics regarding filter lifespan and dialysis effectiveness.

Upcoming Conference Call

To discuss these results and provide deeper insights into Talphera's business strategies, the company will host a conference call and webcast on November 12, 2026, at 4:30 PM ET. Participants can join by dialing in or accessing the webcast via Talphera’s investor relations page.

As Talphera gears up for the next phases of development for nafamostat and addresses regulatory pathways, the company remains committed to filling critical healthcare needs among critically ill patients undergoing renal therapies. With ongoing updates and adjustments to its clinical strategy, Talphera is poised to make significant inroads in the pharmaceutical landscape.

For more detailed information about Talphera, please visit Talphera's website.